Cargando…

(655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients

PURPOSE: Reduction in immunosuppression (IS) is universally recommended in the setting of infection, but its effect on outcomes in the setting of COVID-19 has not been established. The purpose of this study is to characterize the impact of IS reduction strategies on disease severity and outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauers, E., Clark, J., Kotton, C., Lewis, G., Doucette, M., Waldman, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068100/
http://dx.doi.org/10.1016/j.healun.2023.02.669
_version_ 1785018616547115008
author Sauers, E.
Clark, J.
Kotton, C.
Lewis, G.
Doucette, M.
Waldman, G.
author_facet Sauers, E.
Clark, J.
Kotton, C.
Lewis, G.
Doucette, M.
Waldman, G.
author_sort Sauers, E.
collection PubMed
description PURPOSE: Reduction in immunosuppression (IS) is universally recommended in the setting of infection, but its effect on outcomes in the setting of COVID-19 has not been established. The purpose of this study is to characterize the impact of IS reduction strategies on disease severity and outcomes of COVID infection in heart transplant patients (HTPs). METHODS: This was a single center, retrospective review of HTPs with COVID infection managed inpatient or outpatient, examined in cohorts by approach to IS reduction. Demographics, severity at diagnosis and peak based on NIH Classification of COVID Illness Severity, and secondary clinical outcomes were collected (Table 1). The primary outcome was the difference in COVID severity score after IS regimen changes at time of diagnosis. Descriptive statistics, ANOVA, independent t-tests, and chi square analyses were used to evaluate baseline characteristics, primary outcome, and secondary outcomes. RESULTS: Data was collected for 110 patients with 113 COVID infections between March 2020 and June 2022. Patients were on average 54 years old, 75% white, 15% Hispanic ethnicity, and 5 years post HT at the time of their infection. Approaches to IS changes were antimetabolite (antiM) reduction (62%), all IS reduced (6%), or no change (32%). There was a significant difference in clinical severity from diagnosis to peak across all groups (p = 0.004), contributed largely by the All IS Reduced group with significantly higher peak severity (p = 0.002) leading to drastic IS reductions. In a sub-analysis to compare the protocolized approach of antiM reduction to no change in IS, no difference was noted in mortality, superimposed infections, or treated graft rejection (Table 1). Change in severity of infection over time is noted by variant in Figure 1. CONCLUSION: As COVID vaccination and therapeutic agents evolve, drastic IS modifications may not be necessary if baseline infection is mild. However, reduced duration IS reduction did not lead to more treated graft rejection.
format Online
Article
Text
id pubmed-10068100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100681002023-04-03 (655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients Sauers, E. Clark, J. Kotton, C. Lewis, G. Doucette, M. Waldman, G. J Heart Lung Transplant Article PURPOSE: Reduction in immunosuppression (IS) is universally recommended in the setting of infection, but its effect on outcomes in the setting of COVID-19 has not been established. The purpose of this study is to characterize the impact of IS reduction strategies on disease severity and outcomes of COVID infection in heart transplant patients (HTPs). METHODS: This was a single center, retrospective review of HTPs with COVID infection managed inpatient or outpatient, examined in cohorts by approach to IS reduction. Demographics, severity at diagnosis and peak based on NIH Classification of COVID Illness Severity, and secondary clinical outcomes were collected (Table 1). The primary outcome was the difference in COVID severity score after IS regimen changes at time of diagnosis. Descriptive statistics, ANOVA, independent t-tests, and chi square analyses were used to evaluate baseline characteristics, primary outcome, and secondary outcomes. RESULTS: Data was collected for 110 patients with 113 COVID infections between March 2020 and June 2022. Patients were on average 54 years old, 75% white, 15% Hispanic ethnicity, and 5 years post HT at the time of their infection. Approaches to IS changes were antimetabolite (antiM) reduction (62%), all IS reduced (6%), or no change (32%). There was a significant difference in clinical severity from diagnosis to peak across all groups (p = 0.004), contributed largely by the All IS Reduced group with significantly higher peak severity (p = 0.002) leading to drastic IS reductions. In a sub-analysis to compare the protocolized approach of antiM reduction to no change in IS, no difference was noted in mortality, superimposed infections, or treated graft rejection (Table 1). Change in severity of infection over time is noted by variant in Figure 1. CONCLUSION: As COVID vaccination and therapeutic agents evolve, drastic IS modifications may not be necessary if baseline infection is mild. However, reduced duration IS reduction did not lead to more treated graft rejection. Published by Elsevier Inc. 2023-04 2023-04-03 /pmc/articles/PMC10068100/ http://dx.doi.org/10.1016/j.healun.2023.02.669 Text en Copyright © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sauers, E.
Clark, J.
Kotton, C.
Lewis, G.
Doucette, M.
Waldman, G.
(655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
title (655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
title_full (655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
title_fullStr (655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
title_full_unstemmed (655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
title_short (655) Outcomes of Immunosuppression Reduction During Covid-19 Infection in Heart Transplant Patients
title_sort (655) outcomes of immunosuppression reduction during covid-19 infection in heart transplant patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068100/
http://dx.doi.org/10.1016/j.healun.2023.02.669
work_keys_str_mv AT sauerse 655outcomesofimmunosuppressionreductionduringcovid19infectioninhearttransplantpatients
AT clarkj 655outcomesofimmunosuppressionreductionduringcovid19infectioninhearttransplantpatients
AT kottonc 655outcomesofimmunosuppressionreductionduringcovid19infectioninhearttransplantpatients
AT lewisg 655outcomesofimmunosuppressionreductionduringcovid19infectioninhearttransplantpatients
AT doucettem 655outcomesofimmunosuppressionreductionduringcovid19infectioninhearttransplantpatients
AT waldmang 655outcomesofimmunosuppressionreductionduringcovid19infectioninhearttransplantpatients